Tom Brooks
Company direction, partnerships and the commercial relationships behind the pipeline.
About · company, team & partnerships
A project partner for complex APIs.
Not a catalogue and not a broker. Brick 42 is a small, deliberately agile partner that answers the hard go/no-go questions early — years before a generic programme reaches the market.
The company
Small by design. Complex by choice.
We work on the APIs that are hard to make and hard to source — high-potency chemistry, oligonucleotides, anti-virals and biologicals — and we answer the questions that decide a programme before the buyer commits.
The R&D, the funded research and the partnerships keep that work honest: proof that the capability is not a slide, but a route to a transferable process — and a partner who is still there when the programme moves.
- EntityBrick 42 Sagl
- AuthorisationSwissMedic-authorised to trade internationally
- FocusComplex, high-potency active pharmaceutical ingredients
- ModelVirtual and asset-light
- LocationsCadempino, Switzerland · Cleveland, Ohio, USA
- ResearchEU / CH-funded programmes · exerisbio SA joint venture
The team
Who you deal with.
A small leadership team, close to the science and the buyers.
Domenico Badone
Science and R&D — the programmes that prove and extend what Brick 42 can make.
Arnoldo Ardia
Operations and delivery across the company's projects and partnerships.
Partnerships & investment
The collaborations behind the pipeline.
Funded research, a joint venture and an investment in protein research — the route to new molecules and the proof behind the capability claim.
exerisbio SA
A joint venture with Exeris SA — combining process development and scale-up capability with a shared route to complex molecules.
Protein research
An investment in protein research behind the pipeline — expanding the modalities Brick 42 can develop and transfer.
TRANSBORO
An Interreg VI-A Italy–Switzerland (2021–2027) project in Boron Neutron Capture Therapy with UPO, UNIPV and Exeris Bio. The research →
Next
Now ask us the real question.
The company is the context. The molecule and the decision are the conversation.